Pulmonary function tests (PFTs) are critical diagnostic tools that provide valuable insight into respiratory physiology. However, their complexity often poses interpretation challenges for healthcare professionals. This guide aims to clarify the process of interpreting PFT results.
Spirometry is a fundamental component of PFTs. It measures the volume and speed of air that can be inhaled and exhaled, providing data on Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1). In obstructive lung diseases, such as asthma and COPD, the FEV1/FVC ratio is often decreased. Conversely, in restrictive lung diseases, like pulmonary fibrosis, both FEV1 and FVC are reduced, but the ratio remains normal or increased.
The Diffusing capacity of the Lung for Carbon Monoxide (DLCO) evaluates how well gases cross the alveolar-capillary membrane. Reduced DLCO is indicative of conditions affecting gas exchange, such as emphysema or pulmonary fibrosis.
Body plethysmography measures Total Lung Capacity (TLC) and Residual Volume (RV). TLC reduction is a hallmark of restrictive diseases, while an increased RV is seen in obstructive diseases due to air trapping.
Flow-volume loops visually represent the relationship between airflow and lung volume. They can help identify extrathoracic obstructions, intrathoracic obstructions, and fixed obstructions.
Interpreting PFTs is a complex task that requires a comprehensive understanding of respiratory physiology and pathophysiology. This guide provides a basic framework for PFT interpretation, but it is essential to integrate these results with clinical and radiological findings for accurate diagnosis and treatment planning. Continuous education and practice are key to mastering this crucial skill.
1.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
2.
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.
5.
Early breast cancer detection may be possible with a wearable ultrasound scanner.
1.
Integrative Cancer Care: Nutrition, Social Work, Care Coordination, and Genetic Counseling
2.
Tumor Evolution: Signaling, Plasticity, and Intratumor Heterogeneity in Cancer
3.
Essential Perspectives in Hematology and Patient Outcomes
4.
Decoding Hamartomas: Understanding Their Causes and Symptoms
5.
Hematopoietic Recovery Potential and Long-Term Survival: Mechanisms, Clinical Impact, and Emerging Directions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Navigating the Complexities of Ph Negative ALL - Part V
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Signs and Symptoms of Leukemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation